| 翻訳と辞書 |
Metelimumab
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future,〔http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=860002&p_IsPs=N〕 metelimumab was dropped from further development in favour of fresolimumab,〔http://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html〕 which is currently being developed by Genzyme.〔http://www.genzymeoncology.com/onc/research/onc_p_research.asp〕
== History ==
Metelimumab was isolated by Cambridge Antibody Technology (CAT) using its phage display technology. In 2000, CAT signed a collaborative deal with Genzyme to further develop TGF beta antibodies.〔http://prnwire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-28-2000/0001324438&EDATE=〕〔http://www.drugdiscoveryonline.com/article.mvc/Cambridge-Antibody-Genzyme-to-collaborate-on-0001?VNETCOOKIE=NO〕
In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.〔http://goliath.ecnext.com/coms2/gi_0199-693661/CAT-192-is-safe-but.html〕
Initial trials targeted the skin condition scleroderma〔http://www.genzymeoncology.com/onc/clinical/trialdetailresults.asp?nct=NCT00043706〕 but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab,〔 which is currently being developed by Genzyme.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Metelimumab」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|